3D InSight™ Cross-species Hepatotoxicity Testing Service

Evaluate pre-clinical species-specific drug effects in vitro using organotypic 3D liver microtissues

Cross species cover

  • Compare drug-induced liver injury (DILI) in 3D primary liver microtissue models from human, rat, dog, and monkey
  • Perform translational toxicity studies in advanced 3D liver models using a standardized 7 day, repeat-dosing protocol
  • Normalize differential drug/media-component binding effects with a universal testing medium used for all species                                                                                                                          


learn more button no background


Service at a Glance

(View as a PDF)

  • cross species model comp web

    Determine the models in which you want to compare the effect of your drug(s). Choose from advanced 3D liver microtissue models derived from primary rat, dog, monkey, or human hepatocytes.


  • cross species sitax dose response web

    Dose-response curves for Sitaxsentan generated using ATP cell viability assay following 7-day treatment of human, dog, monkey, and rat liver microtissues demonstrating species-specific hepatotoxicity profiles.
  • cross species compatible endpoints web

    Additional endpoints which are compatible with the standard assay setup to support customized translational and mechanistic toxicological queries.
  • Choose from human and animal-derived 3D liver models
  • Determine dose-response of your drug across multiple species in vitro
  • Customize a cross-species investigative study with additional endpoints

Catalog # 3D InSight™ Cross-species Hepatotoxicity Testing
  • SP-07-030-02  Human
  • SP-07-030-01  Rat
  • SP-07-030-03  Dog
  • SP-07-030-04  Monkey
Model systems
(min 2, max 4)
3D InSight™ Human Liver Microtissues (multi-donor hepatocytes, co-culture with Kupffer cells)
3D InSight™ Rat Liver Microtissues (primary hepatocytes, co-culture with NPCs)
3D InSight™ Dog Liver Microtissues (primary hepatocytes, co-culture with Kupffer cells)
3D InSight™ Monkey Liver Microtissues (primary hepatocytes, co-culture with NPCs)
Minimum number of compounds 1  
Standard experimental setup 7 day drug exposure with cell viability endpoint at day 7  
Number of dosings 2 (days 0 and 3)  
Tested compound concentration 7-point dose-response curve  
Positive control compound Chlorpromazine  
Endpoint Dose-dependent intra-tissue ATP content (CellTiter-Glo®, Promega Corp.)  
Data analysis Dose-response for cell viability (IC50ATP)  
Analysis of compound DILI potential in each species based on viability dose-response curves  
Raw data on request  
Written report including material and methods, compound information, graphs, and results summary  
Customization Drug exposure times can be customized (up to 7 days). The number and timing of repeat dosings will vary based on the length of drug exposure. Additional endpoints (including IHC, protein and gene expression, cytokine profiling, etc.) are also available.  

Compound Characterization

Toxicity testing of compounds rated according to likelihood of causing drug-induced liver injury (DILI) in humans. Eight compounds were tested on Human, Dog, Monkey and Rat Liver Microtissues, then categorized by potential DILI severity according to clinical data. Cmax values were taken from human in vivo studies.

cross species cpd characterization table web

Company video